Serina Therapeutics (NYSEAMERICAN:SER) Releases Quarterly Earnings Results

Serina Therapeutics (NYSEAMERICAN:SER) announced its quarterly earnings results on Thursday. The company reported ($0.55) EPS for the quarter, FiscalAI reports.

Serina Therapeutics Price Performance

NYSEAMERICAN SER traded up $0.03 during trading hours on Thursday, hitting $2.85. The company had a trading volume of 53,762 shares, compared to its average volume of 1,883,416. Serina Therapeutics has a 52 week low of $1.22 and a 52 week high of $7.92. The firm has a 50 day simple moving average of $2.06 and a 200 day simple moving average of $2.01. The company has a debt-to-equity ratio of 0.24, a quick ratio of 4.18 and a current ratio of 4.18. The firm has a market capitalization of $42.75 million, a price-to-earnings ratio of -1.43 and a beta of 1.11.

Analysts Set New Price Targets

Separately, BTIG Research initiated coverage on shares of Serina Therapeutics in a research note on Wednesday, July 1st. They issued a “buy” rating and a $8.00 price objective for the company. One analyst has rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $8.00.

Serina Therapeutics Company Profile

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.